Pamela Conley

Dr. Pamela Conley has more than 25 years’ experience discovering and developing both small molecule and biologic therapies for the treatment of cardiovascular disease, inflammation and cancer. Dr. Conley has been an integral part of the Portola team since its inception in 2003, taking on roles of increasing responsibility and contributing to the early- and late-stage development of the Company’s entire portfolio, including the U.S. FDA and European regulatory approvals of andexanet. In her current role, Dr. Conley is responsible for the early research and ongoing development of andexanet and cerdulatinib. Prior to Portola, Dr. Conley was a Senior Director of Biology at Millennium Pharmaceuticals, and a Director at Cor Therapeutics. Dr. Conley has authored more than 50 peer-reviewed manuscripts and is an inventor on multiple US patents.